# Xylometazoline

Section: 28. Ear, nose and throat medicines [c]

EMLc | ATC codes: R01AA07

| | |
|---|---|
| **Indication** | Nasal congestion ICD11 code: MD11.9 |
| **INN** | Xylometazoline |
| **Medicine type** | Chemical agent |
| **List type** | Core |
| **Formulations** | **Local > Nasal > Spray:** 0.05% equivalent to 0.5 mg per mL (EMLc)<br>**Local > Nasal > Drops:** 0.05% equivalent to 0.5 mg per mL (EMLc) |
| **EML status history** | First added in 2009 (TRS 958)<br>Changed in 2021 (TRS 1035)<br>Changed in 2025 (TRS 1064) |
| **Sex** | All |
| **Age** | Children (1 month - 12 years) |
| **Therapeutic alternatives** | Medicines within the same pharmacological class can be used |
| **Therapeutic alternatives limitations for EMLc** | Therapeutic alternatives to be reviewed |
| **Patent information** | Patents have expired in most jurisdictions<br>Read more about patents. |
| **Wikipedia** | Xylometazoline |
| **DrugBank** | Xylometazoline |

## Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of xylometazoline nasal drops 0.05%; - removal of the note regarding use in children less than 3 months.